Genetic variation of the Plasmodium falciparum circumsporozoite protein in parasite isolates from Homabay County in Kenya

M Maina, S Musundi, J Kuja, H Waweru… - Frontiers in …, 2024 - frontiersin.org
The Plasmodium falciparum Circumsporozoite Protein (PfCSP) has been used in
developing the RTS, S, and R21 malaria vaccines. However, genetic polymorphisms within …

First Phase 1b, single-center, age de-escalation trial of the P. falciparum blood-stage malaria vaccine candidate RH5.1/Matrix-M™: a delayed boost regimen induces …

SE Silk, WF Kalinga, J Salkeld, IM Mtaka, S Ahmed… - medRxiv, 2024 - medrxiv.org
Background RH5. 1 is a soluble protein vaccine candidate for blood-stage Plasmodium
falciparum malaria, previously trialed in healthy UK adults in combination with AS01B …

Baseline malaria infection status and RTS, S/AS01E malaria vaccine efficacy

M Juraska, AM Early, L Li, SF Schaffner, M Lievens… - medRxiv, 2023 - medrxiv.org
Background The only licensed malaria vaccine, RTS, S/AS01E, confers moderate protection
against symptomatic disease. Because many malaria infections are asymptomatic, we …

[HTML][HTML] Cross-reactivity of rPvs48/45, a recombinant Plasmodium vivax protein, with sera from Plasmodium falciparum endemic areas of Africa

S Balam, K Miura, I Ayadi, D Konaté, NC Incandela… - bioRxiv, 2024 - ncbi.nlm.nih.gov
Background: Ps48/45, a Plasmodium gametocyte surface protein, is a promising candidate
for malaria transmission-blocking (TB) vaccine. Due to its relevance for a multispecies …

[HTML][HTML] A Potent Kalihinol Analogue Disrupts Apicoplast Function and Vesicular Trafficking in P. falciparum Malaria

Z Chahine, S Abel, T Hollin, JH Chung, GL Barnes… - bioRxiv, 2023 - ncbi.nlm.nih.gov
Here we report the discovery of MED6-189, a new analogue of the kalihinol family of
isocyanoterpene (ICT) natural products. MED6-189 is effective against drug-sensitive and …

Fractional dosing to improve vaccination coverage, vaccine hesitancy, and cost-effectiveness in Africa: a systematic review

A Yacouba, S Brah, M Daou, AK Andia, A Ibrahim… - medRxiv, 2023 - medrxiv.org
Background. The major challenges of vaccination programs are notably coverage in the
target population, vaccine hesitancy, and cost-effectiveness. A vaccination strategy with …

Vaccination with fractional doses: promise or illusion?

F Ntoumi, PG Kremsner - The Lancet Infectious Diseases, 2022 - thelancet.com
In The Lancet Infectious Diseases, Aaron M Samuels and colleagues1 assessed the efficacy
of fractional RTS, S/AS01E (hereafter referred to as RTS, S) vaccines doses against malaria …

Stalled malaria control–root causes and possible remedies

JW Hargrove, GA Vale - medRxiv, 2022 - medrxiv.org
Background Malaria control has been stalled for some years in many African countries. We
suggest reasons for the stalling, and ways of remedying the situation. Methods We analyse …

Immunogenicity and Protection of the mXCL1-PyCSP Fusion Protein Prime-and-Trap DNA Vaccine in a Murine Malaria Immunization/Challenge Model

K Boey - 2024 - search.proquest.com
Malaria is a life-threatening parasitic disease caused by Plasmodium spp. and is transmitted
by female Anopheles spp. mosquitoes. Annually, there are nearly 250 million cases …

Unravelling the predictors of vaccine defaults in Southern Ghana: Evidence from the Malaria RTSS vaccine implementation trial program in the Cape Coast Metropolis

VB Bediako, JA Ackah, TJ Yankey, J Okyere… - 2024 - researchsquare.com
Malaria has been a severe global and public health concern for the last couple of decades.
Ghana, like many other countries in sub–Saharan Africa, is most affected by the disease …